Close Menu
    Facebook X (Twitter) Instagram
    KSA News TodayKSA News Today
    Facebook X (Twitter) Instagram
    • KSA
    • Business
    • Technology
    • Sports
    • Lifestyle
    KSA News TodayKSA News Today
    • KSA
    • Business
    • Technology
    • Sports
    • Lifestyle
    • Contact us
    Lifestyle

    UAE conditionally approves new Ultomiris use for immune-mediated kidney disease

    Editorial TeamBy Editorial TeamNovember 10, 2026
    Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    The UAE just conditionally approved a new use for Ultomiris for immune-mediated kidney disease, after the prescription was first registered in the UAE in 2022 for the treatment of several rare diseases.

    The Emirates Drug Establishment (EDE) granted conditional approval for a new indication of AstraZeneca’s Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.

    Primary IgA nephropathy is an immune-mediated kidney disease caused by the deposition of immune proteins in kidney tissue, potentially leading to inflammation and a gradual decline in kidney function.

    Stay up to date with the latest news. Follow KT on WhatsApp Channels.

    Elevated levels of protein in the urine are an important indicator associated with disease progression, highlighting the importance of treatment options that can reduce proteinuria and help manage the condition.

    EDE stressed the importance of early diagnosis, regular monitoring of kidney function and protein levels in the urine, and adherence to treatment plans prescribed by specialist physicians to support disease management and reduce the risk of complications.

    The approval supports the UAE’s strategic priorities and the objectives of the ‘We the UAE 2031’ vision to strengthen competitiveness in vital sectors, including healthcare and pharmaceuticals, and advance innovation, research and development.

    It also aligns with EDE’s efforts to develop an advanced and proactive pharmaceutical regulatory system based on efficiency, regulatory excellence and international standards of quality, safety and efficacy, while accelerating access to new treatments.

    Source: Khaleej Times

    Previous ArticleMagrabi Health Named Among the World’s Best Hospitals & Clinics for Medical Tourism 2027 by Newsweek
    Next Article Trump demands Israel and other allies it ‘protected’ pay back Iran war costs

    Related Posts

    Garmin Fitness Fest 2026 brings UAE’s fitness community together

    November 21, 2026

    UAE doctors explain why coughs linger for weeks after infections

    November 21, 2026

    How brands can capitalise on the end-of-year rise in spending

    November 20, 2026
    Latest Posts

    Saudi Arabia deports 11,915 illegal residents in a week

    Saudi envoy presents credentials as non-resident ambassador to North Macedonia president

    KSrelief Distributes 1,250 Food Baskets in Yemen’s Shabwa

    Delivery orders surge 25% to over 129 million in Q3 2026

    Latest News

    Garmin Fitness Fest 2026 brings UAE’s fitness community together

    November 21, 2026

    UAE doctors explain why coughs linger for weeks after infections

    November 21, 2026

    How brands can capitalise on the end-of-year rise in spending

    November 20, 2026
    Facebook X (Twitter) Instagram Pinterest
    • KSA
    • Business
    • Technology
    • Sports
    • Lifestyle
    • Contact us
    2026. All rights reserved.

    Type above and press Enter to search. Press Esc to cancel.